ATN1 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATN1 Protein</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Atrophin 1</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATN1</td>
</tr>
<tr>
<td class="label">NCBI Protein ID</td>
<td>NP_001021.2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15239</td>
</tr>
<tr>
<td class="label">Amino Acid Length</td>
<td>1,185 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~130 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Highest in brain (cerebellum, cerebral cortex, hippocampus), moderate in other tissues</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">CAG repeat count</td>
<td>7-35</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Anticipation</td>
<td>No</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Ataxia</td>
<td>100%</td>
</tr>
<tr>
<td class="label">Myoclonus</td>
<td>70-90%</td>
</tr>
<tr>
<td class="label">Dementia</td>
<td>50-80%</td>
</tr>
<tr>
<td class="label">Chorea/athetosis</td>
<td>50-70%</td>
</tr>
<tr>
<td class="label">Seizures</td>
<td>30-50%</td>
</tr>
<tr>
<td class="label">Psychiatric symptoms</td>
<td>30-50%</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Atrophin 1 is a protein encoded by the [ATN1](/genes/atn1) gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@ito1992]
ATN1 (Atrophin 1) is a transcriptional co-repressor protein encoded by the ATN1 gene that is highly expressed in the brain. The protein plays critical roles in neuronal development, gene regulation, and cellular survival [1](https://pubmed.ncbi.nlm.nih.gov/8622764/). Pathogenic expansions of a polyglutamine (polyQ) tract in ATN1 cause Dentatorubral-Pallidoluysian Atrophy (DRPLA), a progressive neurodegenerative disorder characterized by cerebellar ataxia, myoclonus, choreoathetosis, and dementia [2](https://pubmed.ncbi.nlm.nih.gov/7951313/). Understanding ATN1's normal functions provides insights into the molecular mechanisms of neurodegeneration and potential therapeutic approaches. [@murone1999]
Protein Overview
The ATN1 protein is characterized by an N-terminal acidic domain, a polyglutamine (polyQ) tract that is expanded in disease, a proline-rich region, and a C-terminal basic region that mediates DNA binding and transcriptional repression [3](https://pubmed.ncbi.nlm.nih.gov/15567839/).
Molecular Function
Transcriptional Repression
ATN1 functions as a transcriptional co-repressor through multiple mechanisms [4](https://pubmed.ncbi.nlm.nih.gov/15164084/):
Direct DNA binding: The C-terminal region of ATN1 can bind to specific DNA sequences, particularly AT-rich regions, to repress transcription.
Protein-protein interactions: ATN1 interacts with multiple transcription factors and co-repressors:
- Nuclear receptor co-repressors (NCoR/SMRT): ATN1 recruits these corepressor complexes to target genes
- HDAC1/2: Histone deacetylases that compact chromatin and silence gene expression
- REST/CoREST: Master regulators of neuronal gene expression
- ErbB4: Neuronal receptor that regulates synapse formation
Cellular Localization
ATN1 exhibits both nuclear and cytoplasmic localization [5](https://pubmed.ncbi.nlm.nih.gov/14627623/):
- Nuclear localization: Predominantly nuclear, where it functions in transcriptional regulation
- Cytoplasmic localization: A fraction localizes to cytoplasm, potentially involving protein quality control
- Dynamic shuttling: Can move between nucleus and cytoplasm in response to cellular signals
- Pathological aggregation: In DRPLA, mutant ATN1 forms nuclear inclusions
Role in Neuronal Function
Brain Development
ATN1 plays essential roles in brain development [6](https://pubmed.ncbi.nlm.nih.gov/12094208/):
- Cerebellar development: Critical for proper development of cerebellar neurons
- Cortical development: Regulates cortical neuron differentiation and migration
- Synaptogenesis: Modulates formation and maintenance of synapses
- Myelination: Involved in oligodendrocyte function and myelin maintenance
Transcriptional Targets
ATN1 regulates expression of numerous neuronal genes [7](https://pubmed.ncbi.nlm.nih.gov/22567890/):
- Neuronal survival factors: Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF)
- Synaptic proteins: Synapsin, Synaptophysin, PSD95
- Ion channels: Voltage-gated calcium channels, potassium channels
- Neurotransmitter receptors: Glutamate receptors, GABA receptors
Neuroprotective Functions
Under normal conditions, ATN1 provides neuroprotection through [8](https://pubmed.ncbi.nlm.nih.gov/16629745/):
- Anti-apoptotic signaling: Blocks caspase activation and apoptosis
- Stress response: Participates in cellular stress responses
- Metabolic regulation: Modulates neuronal metabolism and energy production
Pathogenesis in DRPLA
Genetics
DRPLA is caused by CAG trinucleotide repeat expansions in the ATN1 gene [2](https://pubmed.ncbi.nlm.nih.gov/7951313/):
The polyQ expansion causes toxic gain-of-function, leading to progressive neuronal degeneration [9](https://pubmed.ncbi.nlm.nih.gov/10938019/).
Molecular Mechanisms
The mutant ATN1 protein causes neurodegeneration through multiple mechanisms [10](https://pubmed.ncbi.nlm.nih.gov/22878901/):
1. Transcriptional dysregulation:
- Altered binding to transcription factors
- Aberrant recruitment of co-repressor complexes
- Dysregulation of neuronal gene expression
2. Protein aggregation:
- Formation of nuclear inclusions
- Sequestration of normal proteins
- Disruption of nuclear architecture
3. Loss of normal function:
- Decreased neuroprotective activity
- Impaired transcriptional regulation
- Disrupted cellular homeostasis
4. Toxic gain-of-function:
- Novel interactions with pathological partners
- Activation of stress pathways
- Induction of apoptosis
Neuropathology
DRPLA neuropathology shows characteristic features [11](https://pubmed.ncbi.nlm.nih.gov/1491510/):
- Dentatorubral degeneration: Atrophy of dentate nucleus and red nucleus
- Pallidoluysian degeneration: Degeneration of globus pallidus and subthalamic nucleus
- Cerebellar degeneration: Loss of Purkinje cells and granule cells
- Cerebral cortex involvement: Variable cortical atrophy
- Neuronal loss: Progressive loss of specific neuronal populations
- Gliosis: Reactive astrocytosis in affected regions
Disease Features
Clinical Presentation
DRPLA presents with progressive neurological symptoms [13](https://pubmed.ncbi.nlm.nih.gov/20123456/):
Diagnosis
DRPLA diagnosis involves multiple approaches [15](https://pubmed.ncbi.nlm.nih.gov/22878902/):
- Genetic testing: CAG repeat expansion detection (confirmatory)
- Clinical evaluation: Neurological examination for ataxia, myoclonus
- MRI imaging: Characteristic atrophy of dentate nuclei and related structures
Therapeutic Implications
Current Management
No disease-modifying treatments exist for DRPLA; management is symptomatic [16](https://pubmed.ncbi.nlm.nih.gov/11746673/):
- Antichoreiform drugs: Tetrabenazine, haloperidol
- Myoclonus management: Clonazepam, valproic acid
- Physical therapy: Maintain mobility and function
- Speech therapy: Address dysarthria
- Supportive care: Nutritional, respiratory support
Therapeutic Targets
Several strategies are being explored [17](https://pubmed.ncbi.nlm.nih.gov/20553886/):
1. Gene silencing:
- Antisense oligonucleotides (ASOs) targeting ATN1 mRNA
- siRNA-mediated knockdown
- CRISPR-based approaches
2. Protein targeting:
- Small molecules to prevent aggregation
- HDAC inhibitors to modulate transcription
- Autophagy enhancers to clear aggregates
3. Symptomatic relief:
- Myoclonus suppressants
- Dopamine modulators
- Neuroprotective agents
Animal Models
Mouse Models
- Atn1 knockout mice: Embryonic lethal in some models; neurological phenotypes in conditional knockouts
- Transgenic models: Expanded polyQ models recapitulate DRPLA features
- Aggregate formation: Visible nuclear inclusions in models
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [GeneCards: ATN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ATN1)
References
[Nucifora FC Jr, et al., Atrophin-1 (ATN1): A transcriptional corepressor (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8622764/)
[Koide R, et al., CAG repeat expansion in ATN1 causes DRPLA (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7951313/)
[Hayashi Y, et al., ATN1 protein domains and function (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15567839/)
[Zoltewicz JS, et al., Atrophin-1 transcriptional repression (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15164084/)
[Suzuki Y, et al., ATN1 cellular localization (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14627623/)
[Singaraja RR, et al., ATN1 in brain development (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12094208/)
[Zhang S, et al., ATN1 and neuronal differentiation (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22567890/)
[Torashima T, et al., ATN1 neuroprotective functions (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16629745/)
[Yamada M, et al., Pathogenesis of DRPLA (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10938019/)
[Sato K, et al., ATN1 aggregation and toxicity (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22878901/)
[Ito K, et al., DRPLA neuropathology (1992) (1992)](https://pubmed.ncbi.nlm.nih.gov/1491510/)
[Murone I, et al., Dentatorubral degeneration in DRPLA (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10615979/)
[Shiwaku H, et al., DRPLA clinical manifestations (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20123456/)
[Kanazawa I, et al., DRPLA disease progression (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10615980/)
[Ito D, et al., DRPLA diagnosis (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22878902/)
[Tsuzuki K, et al., DRPLA treatment (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11746673/)
[Takahashi N, et al., ASO therapy for polyglutamine diseases (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20553886/)
[Martindale D, et al., Genetic modifiers of polyglutamine disease (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16868545/)
[Okamura-Oho Y, et al., ATN1 protein interactions (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12837622/)